Home-Based SARS-CoV-2 Antigen Testing Could Aid Pandemic Control
Investigators adapted a simple compartmental epidemic model to simulate SARS-CoV-2 spread, death, and associated costs in the US in an effort to understand the role of at home testing.
All articles by Jessica Nye
A Closer Look at Cardiovascular Complications of Malaria
The researchers’ goals include systematically reviewing the existing evidence of cardiovascular involvement in infectious diseases, including tropical infectious diseases.
Lower-Sodium Oxybate Improved Daytime Sleepiness in Patients With Idiopathic Hypersomnia
In this study to be presented at the AAN 2021 Virtual Annual Meeting, researchers evaluated the safety and efficacy of lower-sodium oxybate (LXB) in adult participants with idiopathic hypersomnia.
NAAT Nasopharyngeal Swabs Still Gold Standard for Diagnosing SARS-CoV-2
Researchers systematically reviewed literature to understand the performance and sensitivity of alternative sample types compared with that of nasopharyngeal swabs for the diagnosis of SARS-CoV-2.
Expansion of SARS-CoV-2 Surveillance Required for Epidemic Prevention
Study authors assessed the economic trade-offs of expanding and accelerating testing for SARS-CoV-2 across the United States in different transmission scenarios.
HIV Infection Increases Risk for Severe COVID-19, COVID-19-Related Mortality
Study authors evaluated the association between HIV diagnosis and COVID-19 diagnosis, hospitalization, and in-hospital death in New York State.
High Efficacy of Pfizer COVID-19 Vaccine in a Nationwide Mass Vaccination Program
Study authors analyzed data from Israel’s largest health care organization to evaluate the effectiveness of Pfizer’s COVID-19 mRNA vaccine, BNT162b2, in a real world setting.
CDC: Most Transmission of COVID-19 Likely From Asymptomatic or Presymptomatic Individuals
Investigators from the CDC determined that the proportion of SARS-CoV-2 transmission in the community is likely to occur from individuals who are asymptomatic.
The Pfizer and BioNTech mRNA Vaccine for COVID-19 Conferred 95% Protection With a Satisfactory Safety Profile
Pfizer and BioNTech release safety and efficacy data from phase 2/3 trials for their COVID-19 mRNA vaccine.
Inequities Likely to Blame for Racial Disparities of COVID-19
Further research is needed to identify possible interventions that may mitigate the racial disparities seen in COVID-19.
-
Loading...
-
Loading...
Next post in General Neurology
